Research programme: rare disease therapeutics - Shire/Cincinnati Children's Hospital Medical CenterAlternative Names: Orphan disease therapeutics - Shire/Cincinnati Children's Hospital Medical Center
Latest Information Update: 17 Apr 2015
At a glance
- Originator Cincinnati Childrens Hospital Medical Center; Shire
- Developer Cincinnati Childrens Hospital Medical Center
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 17 Apr 2015 Early research in rare disease indications in USA (unspecified route)